In a report released today, Cory Kasimov from J.P. Morgan maintained a Buy rating on Seagen (SGEN – Research Report), with a price target of $194.00. The company’s shares closed last Thursday at $177.43.
According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 17.0% and a 55.1% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Ultragenyx Pharmaceutical, and ACADIA Pharmaceuticals.
Seagen has an analyst consensus of Moderate Buy, with a price target consensus of $181.00, a 2.4% upside from current levels. In a report issued on July 15, Morgan Stanley also maintained a Buy rating on the stock with a $180.00 price target.
Seagen’s market cap is currently $32.66B and has a P/E ratio of -47.01.
Based on the recent corporate insider activity of 76 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SGEN in relation to earlier this year. Last month, Vaughn Himes, the CTO of SGEN bought 1,134 shares for a total of $46,539.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Washington-based Seagen, Inc. is a biotechnology company, which is focused on developing and commercializing innovative, empowered monoclonal antibody-based therapies for the treatment of cancer. Its products include Adcetris and Padcev.
Read More on SGEN: